Phase II/III Clinical Trial Failure Rate Exceeds 60%, Wasting Billions Annually

More than 30% of drugs fail in Phase II and 58%+ fail in Phase III. CNS drugs fail at ~85%. The average Phase III trial costs $36.58M (2024), 30% higher than 2018. The overall success rate from Phase I to approval is approximately 8-11%, meaning 9 out of 10 compounds fail.

Phase III trials that bypassed or overrode negative Phase II results showed only 31% positive outcome rate versus 57% for those with solid Phase II foundations. The core issue: preclinical animal models poorly predict human efficacy. Mouse models of cancer, Alzheimer's, and inflammation have notoriously poor translation rates. Target validation remains the weakest link — >50% of Phase II failures are due to lack of efficacy, not safety.

Why It Matters

Developing a new drug costs $1.3-2.6B average. A failed Phase III trial wastes $36.58M average (2024 data). The biopharma industry spent $238B on R&D in 2023. Better prediction could save $50B+ annually and bring life-saving drugs to patients faster.

Startup Approach

Build better clinical trial prediction platform using real-world evidence, multi-omic patient data, and AI to identify which compounds will succeed before expensive Phase III trials. Or develop organ-on-chip/microphysiological systems that predict human drug response better than animal models.

NIH Funding

NCATS 2025-2030 Strategic Plan prioritizes AI/ML for drug discovery. NCATS labs combine automation and AI/ML to advance biological and chemical discoveries. NCATS explores quantum methods in AI-based drug discovery.

Who's Working On It

NCATS (translational science programs), Recursion Pharmaceuticals (AI drug discovery), Isomorphic Labs (DeepMind/Alphabet), Insilico Medicine (AI-designed drug in Phase II), Valo Health (AI-driven clinical predictions)